Effect of withdrawal of statin on C-reactive protein

被引:39
|
作者
Lee, KT
Lai, WT
Chu, CS
Tsai, LY
Yen, HW
Voon, WC
Sheu, SH
机构
[1] Kaohsiung Med Univ Hosp, Dept Internal Med, Cardiol Sect, Kaohsiung 80708, Taiwan
[2] Kaohsiung Med Univ Hosp, Dept Clin Chem, Kaohsiung 80708, Taiwan
关键词
hyperlipidemia; statin; C-reactive protein;
D O I
10.1159/000080486
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: C-reactive protein is considered a risk factor for coronary artery disease. In addition to its lipid-lowering properties, statin decreases the level of C-reactive protein. Abrupt cessation of statin therapy during treatment could increase the incidence of cardiac events in patients with atherosclerotic heart disease. The changes of C-reactive protein after withdrawal of statin therapy are still unknown. Methods: Twenty patients with hyperlipidemia received statin (atorvastatin, 10 mg/day) therapy for 3 months. The levels of lipid profiles and C-reactive protein were assessed before receiving the statin therapy, immediately after 3 months of therapy, and on the 3 consecutive days after withdrawal of statin treatment. Results: After 3 months of statin therapy, the total cholesterol, low-density lipoprotein cholesterol (LDL-chol), and C-reactive protein were significantly reduced (264.94 +/- 16.23 vs. 183.44 +/- 16.34 mg/dl, 183.17 +/- 34.56 vs. 122.00 +/- 17.66 mg/dl, and 2,309.00 +/- 437.85 vs. 1,257.95 +/- 207.99 ng/ml, respectively). The level of C-reactive protein increased on the second day after withdrawal of statin therapy (2,590.14 +/- 1,045.05 vs. 1,257.95 +/- 207.99 ng/ml); however, the total cholesterol and LDL-chol did not increase during the 3-day period after withdrawal of statin therapy. Conclusions: The increase in the level of C-reactive protein after withdrawal of statin therapy may be a contributing factor to the increased incidence of cardiac events in patients who have abruptly stopped statin therapy. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:166 / 170
页数:5
相关论文
共 50 条
  • [1] Role of C-Reactive Protein When Prescribing a Statin
    Scott Kinlay
    Current Atherosclerosis Reports, 2012, 14 : 26 - 32
  • [3] Relating statin therapy to C-reactive protein levels
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (09) : 1597 - 1600
  • [4] Models for the analysis of C-reactive protein in statin trials
    Southworth, Harry
    Dane, Aaron
    PHARMACEUTICAL STATISTICS, 2009, 8 (02) : 87 - 97
  • [5] C-Reactive protein levels and outcomes after statin therapy
    不详
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2005, 12 (02): : 187 - 188
  • [6] C-reactive protein changes with anti hypertensive and statin treatment
    Rodilla, E
    Gómez-Belda, A
    Costa, JA
    Aragó, M
    Miralles, A
    González, C
    Pascual, JM
    MEDICINA CLINICA, 2005, 125 (15): : 561 - 564
  • [7] C-reactive protein levels and outcomes after statin therapy
    Ridker, PM
    Cannon, CP
    Morrow, D
    Rifai, N
    Rose, LM
    McCabe, CH
    Pfeffer, MA
    Braunwald, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (01): : 20 - 28
  • [8] C-reactive protein levels and outcomes after statin therapy
    Greenland, P
    Lloyd-Jones, DM
    Moss, AJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (15): : 1603 - 1604
  • [9] High-Sensitivity C-Reactive Protein and Statin Initiation
    Trpkovic, Andreja
    Stanimirovic, Julijana
    Rizzo, Manfredi
    Resanovic, Ivana
    Soskic, Sanja
    Jevremovic, Danimir
    Isenovic, Esma R.
    ANGIOLOGY, 2015, 66 (06) : 503 - 507
  • [10] An analysis of C-reactive protein and the efficacy of ezetimibe added to statin therapy
    Pearson, T
    Denke, M
    McBride, P
    Battisti, WP
    Brady, WE
    Palmisano, J
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 74 - 74